Abstract
Background: The incidence of mesothelioma is rising rapidly in the UK. There is no generally accepted standard treatment. The BTS recommends active symptom control (ASC). It is not known whether chemotherapy in addition prolongs survival or provides worthwhile palliation with acceptable toxicity. Palliation as recorded by patients has been fully reported for only two regimens: mitomycin, vinblastine, and cisplatin (MVP), and vinorelbine (N). The BTS and collaborators planned to conduct a phase III randomised trial comparing ASC only, ASC+MVP, and ASC+N in 840 patients with survival as the primary outcome measure. The aim of the present study was to assess the acceptability of the trial design to patients and the suitability of two standard quality of life (QL) questionnaires for mesothelioma.
Methods: Collaborating centres registered all new patients with mesothelioma. Those eligible and giving informed consent completed EORTC QLQ-C30+LC13 and FACT-L QL questionnaires and were randomised between all three or any two of (1) ASC only, (2) ASC+4 cycles of MVP, and (3) ASC+12 weekly doses of N.
Results: During 1 year, 242 patients were registered of whom 109 (45%) were randomised (55% of the 197 eligible patients). Fifty two patients from 20 centres were randomised to an option including ASC only. This translates into a rate of 312 per year from 60 centres interested in collaborating in the phase III trial. The EORTC QL questionnaire was superior to FACT-L in terms of completeness of data and patient preference. Clinically relevant palliation was achieved with ASC.
Conclusion: The planned phase III trial is feasible.
Full Text
The Full Text of this article is available as a PDF (222.3 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Berghmans T., Paesmans M., Lalami Y., Louviaux I., Luce S., Mascaux C., Meert A. P., Sculier J. P. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer. 2002 Nov;38(2):111–121. doi: 10.1016/s0169-5002(02)00180-0. [DOI] [PubMed] [Google Scholar]
- Chahinian A. P., Antman K., Goutsou M., Corson J. M., Suzuki Y., Modeas C., Herndon J. E., 2nd, Aisner J., Ellison R. R., Leone L. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol. 1993 Aug;11(8):1559–1565. doi: 10.1200/JCO.1993.11.8.1559. [DOI] [PubMed] [Google Scholar]
- Middleton G. W., Smith I. E., O'Brien M. E., Norton A., Hickish T., Priest K., Spencer L., Ashley S. Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol. 1998 Mar;9(3):269–273. doi: 10.1023/a:1008236010868. [DOI] [PubMed] [Google Scholar]
- Peto J., Decarli A., La Vecchia C., Levi F., Negri E. The European mesothelioma epidemic. Br J Cancer. 1999 Feb;79(3-4):666–672. doi: 10.1038/sj.bjc.6690105. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Peto J., Hodgson J. T., Matthews F. E., Jones J. R. Continuing increase in mesothelioma mortality in Britain. Lancet. 1995 Mar 4;345(8949):535–539. doi: 10.1016/s0140-6736(95)90462-x. [DOI] [PubMed] [Google Scholar]
- Ryan C. W., Herndon J., Vogelzang N. J. A review of chemotherapy trials for malignant mesothelioma. Chest. 1998 Jan;113(1 Suppl):66S–73S. doi: 10.1378/chest.113.1_supplement.66s. [DOI] [PubMed] [Google Scholar]
- Samson M. K., Wasser L. P., Borden E. C., Wanebo H. J., Creech R. H., Phillips M., Baker L. H. Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study. J Clin Oncol. 1987 Jan;5(1):86–91. doi: 10.1200/JCO.1987.5.1.86. [DOI] [PubMed] [Google Scholar]
- Steele J. P. C. The new front line treatment for malignant pleural mesothelioma? Thorax. 2003 Feb;58(2):96–97. doi: 10.1136/thorax.58.2.96. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Steele J. P., Shamash J., Evans M. T., Gower N. H., Tischkowitz M. D., Rudd R. M. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol. 2000 Dec 1;18(23):3912–3917. doi: 10.1200/JCO.2000.18.23.3912. [DOI] [PubMed] [Google Scholar]
- Stephens R. J., Hopwood P., Girling D. J. Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise. Br J Cancer. 1999 Feb;79(3-4):538–544. doi: 10.1038/sj.bjc.6690085. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sørensen P. G., Bach F., Bork E., Hansen H. H. Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma. Cancer Treat Rep. 1985 Dec;69(12):1431–1432. [PubMed] [Google Scholar]